Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D00HZA
|
|||
Former ID |
DIB013895
|
|||
Drug Name |
YPEG-Somatropin
|
|||
Synonyms |
YPEG-Somatropin (growth hormone deficiency)
Click to Show/Hide
|
|||
Indication | Growth hormone deficiency [ICD-11: 5A61.3] | Phase 1 | [1] | |
Company |
Xiamen Amoytop Biotech Co Ltd
|
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Somatotropin (GH1) | Target Info | Modulator | [2] |
KEGG Pathway | Cytokine-cytokine receptor interaction | |||
Neuroactive ligand-receptor interaction | ||||
PI3K-Akt signaling pathway | ||||
Jak-STAT signaling pathway | ||||
Reactome | Prolactin receptor signaling | |||
Growth hormone receptor signaling | ||||
WikiPathways | Endochondral Ossification | |||
Prolactin receptor signaling | ||||
Growth hormone receptor signaling | ||||
Adipogenesis | ||||
Synthesis, Secretion, and Deacylation of Ghrelin |
References | Top | |||
---|---|---|---|---|
REF 1 | ClinicalTrials.gov (NCT01339182) Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of Pegylated-Somatropin in Healthy Volunteers. U.S. National Institutes of Health. | |||
REF 2 | Somatropin therapy in adults with Prader-Willi syndrome. Treat Endocrinol. 2004;3(3):153-60. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.